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Sunitinib is approved for the treatment of metastatic renal cell carcinoma (RCC) and imatinib-resistant or -intolerant gastrointestinal
stromal tumours (GIST). Several studies have identified unexpected rates of thyroid dysfunction with sunitinib treatment. We
performed a prospective observational study with the aim of more accurately defining the incidence and severity of hypothyroidism in
RCC or GIST patients receiving sunitinib. Thyroid function was assessed at baseline and on days 1 and 28 of each treatment cycle.
Thyroid antibodies were assessed at baseline and during follow-up if abnormal thyroid function tests were recorded. Sixteen patients
(27%) developed sub- or clinical hypothyroidism and required hormone replacement and 20 patients (34%) showed at least one
elevated thyroid-stimulating hormone not requiring therapeutic intervention. Twenty patients (34%) did not develop any biochemical
thyroid abnormality. Thus, sunitinib can induce (sub-) clinical hypothyroidism, warranting close monitoring of thyroid function.
We propose a new algorithm for managing this side effect in clinical practise.
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Sunitinib (SUTENT; Pfizer Inc., New York NY, USA) is
an oral multitargeted tyrosine kinase inhibitor with both anti-
angiogenic and anti-tumor activities mediated by signal blockade
of several receptors, including VEGFR-1, -2 and -3; KIT; PDGFR-a
and PDGFR-b; FLT-3; CSF-1 and RET (Chow and Eckhardt, 2007;
Roskoski Jr 2007). Its efficacy in metastatic renal cell carcinoma
(RCC) (Motzer et al, 2006) and in imatinib-resistant or -intolerant
gastrointestinal stromal tumours (GIST) (Demetri et al, 2006) led
to Food and Drug Administration (FDA) and European Medicines
Agency (EMEA) approval for treatment of these cancers
(Goodman et al, 2007; Rock et al, 2007). Sunitinib may also be
beneficial in other malignancies, including neuroendocrine, breast,
colon and non-small-cell lung cancer (Saltz et al, 2007; Burstein
et al, 2008; Socinski et al, 2008).
Our group has gained clinical experience with sunitinib
administration, primarily in patients with RCC and GIST
(Scho ¨ffski et al, 2006a,b; Wolter et al, 2007), since 2005. Having
first identified sporadic cases of thyroid dysfunction during
sunitinib treatment, we evaluated this phenomenon in a limited
number of patients, both retrospectively (n¼14) and prospec-
tively (n¼19) (Scho ¨ffski et al, 2006b). In both studies, we found an
unexpected high frequency of hypothyroidism (57 and 37%,
respectively). This uncommon drug-induced side effect was not
previously identified in clinical trials, in which sunitinib toxicities
included fatigue, nausea, vomiting, hand-foot-skin reaction, rash,
hypertension and/or diarrhoea (Demetri et al, 2006; Faivre et al,
2006; Motzer et al, 2006). An association between sunitinib
treatment and thyroid dysfunction has been also described by
other groups (Desai et al, 2006; Martorella et al, 2006; Shaheen
et al, 2006; Mannavola et al, 2007; Rini et al, 2007; Wong et al,
2007). However, the previous studies were limited by factors
related to study design including variable definition of hypo-
thyroidism, incomplete panel of thyroid function tests (TFTs) or
lack of measurements for all patients and inclusion of patients with
underlying thyroid disorders.
Here, we present the results of our prospective evaluation of
incidence and severity of the new-onset hypothyroidism in a larger
number of sunitinib-treated cancer patients (n¼59). We include
clearly defined exclusion criteria, baseline thyroid-stimulating
hormone (TSH) values in all patients and thyroid antibodies in the
majority of patients, as well as systematically evaluating TFTs
during treatment. Furthermore, we discuss comparatively our
study with the currently available data on sunitinib-induced
thyroid dysfunction, and propose for the first time an algorithm
for routine treatment of this clinical phenomenon.
PATIENTS AND METHODS
Patients and treatment schedule
Our single-centre, prospective, observational study included
patients receiving sunitinib in the Department of General Medical
Oncology at the University Hospital Gasthuisberg (Leuven,
Belgium). Between November 2005 and June 2007, a total of
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s74 patients received sunitinib for metastatic, immunotherapy-
resistant RCC or imatinib-refractory or -intolerant GIST. Patients
with abnormal TFTs at baseline (before sunitinib initiation), with
previous thyroid hormone replacement due to underlying thyroid
disease or under sunitinib treatment for less than 4 weeks, were
excluded from the study. Patients had no food restriction, and
medication other than sunitinib was not standardised. Sunitinib
50mgday
 1 was administered orally for 4 weeks, followed by a
2-week rest period. Doses were adjusted based on haematological
and non-haematological adverse events, according to the manu-
facturer’s recommendations. Study end points included the
incidence and severity of sunitinib-induced thyroid dysfunction.
Evaluation of thyroid function
All patients had thyroid function assessed at baseline and on days
1 and 28 of each treatment cycle, which was determined by serum
TSH, total triiodotyronine (T3) and the free thyroxine index (FTI)
calculated from total thyroxine (T4) and the residual T-uptake.
Antibodies against thyroid peroxidase (TPOAb), thyroglobulin
(TgAb) and the TSH receptor (TR-Ab) were also assessed at
baseline in most patients and during follow-up if abnormal TFTs
were recorded. Reverse T3 and Tg were also measured in patients
with abnormal TFTs. Serum TSH, total T3, T4 and T-uptake were
measured by an electrochemiluminescent immunoassay (ECLIA;
Roche, Mannheim, Germany); TPOAb and TgAb by a radioligand
assay (Brahms, Henningsdorf, Germany); and TR-Ab by a radio
receptor assay (Brahms). Serum samples were collected, handled
and analysed according to internal standard operating procedures.
Our laboratory reference ranges are 0.27–4.20mIUl
 1 for TSH;
5.1–14.1mgdl
 1 for total T4; 80–200ngdl
 1 for total T3; 4.8–12.7
for FTI; and 80–130% for T-uptake. The cutoff level for TPOAb
is 100Uml
 1. Antibodies against thyroglobulin 4200Uml
 1 is
considered positive. Antibodies against thyroglobulin o1IUl- is
considered negative and 41.5IUl
 1 as positive.
Definition of hypothyroidism and hyperthyroidism
The biochemical diagnosis of subclinical hypothyroidism and
hyperthyroidism was determined in accordance with guidelines of
the American Thyroid Association (ATA), the American Associa-
tion of Clinical Endocrinologists (AACE) and the Endocrine
Society (Surks et al, 1990, 2004). Subclinical hypothyroidism is
considered as serum TSH above the upper limit of normal
(ULN¼4.20mIUl
 1 in our laboratory), with FTI within normal
limits. Clinical hypothyroidism is defined as low serum FTI
together with elevated TSH. Subclinical hyperthyroidism is defined
as serum TSH below the lower limit of normal (LLN¼0.27mIUl
 1
in our laboratory), with serum T4 and T3 within normal ranges.
Overt hyperthyroidism is considered as low TSH and elevated FTI.
Patients with overt hypothyroidism and those with at least
two consecutive TSH measurements 410mIUl
 1 and symptoms
compatible with hypothyroidism (e.g., fatigue, cold intolerance,
constipation or weight gain) received thyroid hormone replace-
ment therapy with L-thyroxine. Target TSH concentration for
replacement intervention was 0.5–2mIUl
 1. All patients with
overt hyperthyroidism and symptoms compatible with hyper-
thyroidism (e.g., anxiety, weakness, tremor, palpitations, heat
intolerance, increased perspiration and weight loss, despite a
normal or increased appetite and diarrhoea) were treated.
RESULTS
Patient characteristics
In total, 59 out of 74 patients were eligible for evaluation. Of the
15 patients who were excluded from the study, 5 patients had
abnormal baseline TFTs, 4 patients were already receiving thyroid
hormone replacement due to underlying thyroid disease and 6
patients received sunitinib treatment for less than 4 weeks. The
percentage of patients with abnormal baseline TFTs (7%) agrees
with the expected prevalence of thyroid dysfunction in the general
population. Demographics, disease and treatment characteristics
of the 59 eligible patients are presented in Table 1. Almost two-
thirds of eligible patients had RCC (n¼42), with the majority
having clear cell histology, with the remainder belonging to the
GIST cohort (n¼17). The patient median age/range and gender
ratio was similar for the two cohorts. Prior treatment included
interleukin-2 and/or interferon-a for the RCC group and imatinib
for the GIST group. In the total study population (n¼59), median
TSH at baseline was 1.47mIUl
 1 (range 0.28–3.94), which was
within our laboratory reference range. Overall, median treatment
with sunitinib was 29 weeks (range 4–82), with a slightly more
prolonged median follow-up of 34 weeks (range 4–88). Haema-
tological or non-haematological grade III and IV toxicities were
observed in 18 (43%) RCC and 6 (35%) GIST patients.
Thyroid function during sunitinib administration
Table 2 provides a summary of TFT results in both RCC and GIST
cohorts during sunitinib treatment. We followed ATA, AACE and
the Endocrine Society guidelines to establish a biochemical
diagnosis of subclinical hypothyroidism and hyperthyroidism
(Surks et al, 1990, 2004). Although there is some controversy as
to whether the TSH ULN should be reduced, we considered TSH
44.20mIUl
 1 to be elevated. Only 20 patients (34%) had no
biochemical thyroid abnormality. Twenty patients (34%) showed
at least one elevated TSH not requiring therapeutic intervention
and 16 (27%) patients developed sub- or clinical hypothyroidism
requiring treatment. In three patients (5%) at least one serum TSH
fell below the LLN (LLN¼0.27mIUl
 1), with serum T4 and T3
within normal ranges.
We observed TSH levels of up to 120mIUl
 1, approximately
30-fold ULN. Thyroid-stimulating hormone elevation can be
quite substantial even within one sunitinib cycle, as observed,
for instance, in one patient, from a normal 0.19 to a high
of 78.63mIUl
 1. In most patients, such high levels of TSH were
accompanied by typical features of hypothyroidism, such as
progressive fatigue, myalgia, cold intolerance and constipation. We
did not encounter myxoedema coma cases, but such cases may
exist, as demonstrated by the study of Mannavola et al (2007).
Thyroid function abnormalities were detected relatively early
during treatment, with median time to abnormal TSH of 4 weeks
Table 1 Patient/treatment characteristics
Cohort RCC GIST RCC+GIST
No. of patients 42 17 59
Male, n (%) 31 (74) 13 (76) 44 (75)
Female, n (%) 11 (26) 4 (24) 15 (25)
Median age at start, years
(range)
61.5 (42–77) 61 (42–74) 61 (42–77)
Prior nephrectomy, n (%) 39 (93) NA 39 (66)
Prior treatment, n (%) 39 (93)
a 17 (100)
b 56 (95)
Histology, n (%)
Clear cell 38 (90) NA
Chromophobe 1 (2.5)
Papillary 1 (2.5)
Mixed 2 (5)
Median treatment time with
sunitinib, weeks (range)
29 (4–82) 33 (10–82) 29 (4–82)
Patients with sunitinib
dose reductions, n (%)
18 (43) 6 (35) 24 (41)
GIST¼gastrointestinal stromal tumour; NA¼not applicable; RCC¼renal cell
carcinoma.
aIL-2/INF-a.
bImatinib.
Thyroid dysfunction with sunitinib treatment
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s(range 2–46). Representative courses of TSH levels in three
patients treated with sunitinib are presented in Figure 1A–C. Note
the characteristic alternate course of TSH concentrations (zigzag
shape), with normal levels at baseline, elevated on day 28 of a
4-week treatment cycle, and normalised at the end of the 2-week
rest period. In patients experiencing TFT abnormalities, such
pattern was observed during most cycles of sunitinib treatment. In
the 16 patients developing (sub)clinical hypothyroidism requiring
hormone replacement, median TSH at baseline was 1.45mIUl
 1
(range 0.59–3.94), increased to a median of 8.15mIUl
 1 (range
2.61–26.32) by day 28 of the first cycle, and decreased to a median
of 2.5mIUl
 1 (range 0.92–13.23) by day 1 of the second cycle.
A similar pattern was also found in the subgroup of patients with
at least one elevated TSH without requiring treatment; however,
the increase in TSH was more moderate. Thus, for these patients,
median TSH at baseline was 1.96mIUl
 1 (range 0.78–3.9), rose by
day 28 of the first sunitinib cycle to 3.65mIUl
 1 (range 1.15–7.22),
and dropped by day 1 of the second cycle to a median of
2.14mIUl
 1 (range 0.52–4.08) (Figure 1D).
The median duration of sunitinib treatment in the group
developing hypothyroidism was 48 weeks (range 4–81), which is
much longer than in the group with no thyroid function
abnormality (21 weeks; range 4–82). The percentage of patients
with (sub)clinical hypothyroidism requiring treatment was higher
in the RCC group (33%) than in the GIST group (12%). Dose
reductions for grades III–IV haematological and non-haemato-
logical toxicities were more frequent in the hypothyroid group
than in the normal thyroid group.
Subclinical hypothyroidism was preceded by a short period
of low TSH and elevated T3/T4 in 4 out of the 16 patients
developing hypothyroidism. Although TPOAb was negative in all
four patients, ultrasound revealed thyroid hypovascularity and
serum Tg was elevated in 2, suggesting underlying drug-induced
thyroiditis.
Low titres of TPOAb were found in only 2 (4%) out of 49 total
evaluable patients, whereas TgAb and TR-Ab were positive in
2 and 1 patients, respectively.
DISCUSSION
Our study prospectively analysed the occurrence and severity of
hypothyroidism in cancer patients receiving sunitinib. Our patient
population comprises 59 patients, the majority of whom had
metastatic cytokine-resistant RCC, and the rest had imatinib-
resistant or -intolerant GIST. Although our study confirms that
sunitinib may induce biochemical and clinical hypothyroidism, it
adds several features compared with previously published studies
(Table 3). The definition of hypothyroidism was somewhat
variable in previous studies. Other limitations include lack of
complete TFTs before or during treatment, and/or measurements
available in some but not all patients. When our manuscript was in
Table 2 Thyroid function during sunitinib treatment
Cohort RCC (n¼42) GIST (n¼17) RCC+GIST (n¼59)
No biochemical thyroid abnormalities, n (%) 11 (26) 9 (53) 20 (34)
Median time to abnormal TSH, weeks (range) 4 (2–22) 9 (4–46) 4 (2–46)
At least one m TSH (no treatment required), n (%) 14 (33) 6 (35) 20 (34)
(Sub)clinical hypothyroidism (treatment required), n (%) 14 (33) 2 (12) 16 (27)
At least one k TSH (no treatment required), n (%) 3 (7) 0 3 (5)
(Sub)clinical hyperthyroidism (treatment required), n (%) 0 0 0
TPOAb-positive patients 2
a 0
b 2
GIST¼gastrointestinal stromal tumour; NA¼not applicable; RCC¼renal cell carcinoma.
aTPOAb measurements available in 38 out of 42 patients with RCC.
bTPOAb
measurements available in 11 out of 17 patients with GIST.
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Figure 1 Representative courses of TSH (mIUl
 1) in three patients receiving sunitinib (A–C); median TSH during first cycles of sunitinib treatment based
on severity of thyroid dysfunction (D).
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spreparation, Mannavola et al published results from a prospective
evaluation, involving a smaller number of patients (n¼24)
(Mannavola et al, 2007).
Following initiation of sunitinib, one-third of patients did not
develop any biochemical TFT abnormalities. We observed a
transient elevation of TSH in 34% of cases and (sub)clinical
primary hypothyroidism requiring treatment in a further 27% of
patients. As all patients had normal thyroid function at baseline,
the latter percentage applies to the new-onset hypothyroidism. The
frequency of (sub)clinical hypothyroidism in sunitinib-treated
patients varies substantially among the reported studies (Table 3),
but is up to 10-fold higher than the occurrence of hypothyroidism
in the general population (Laurberg et al, 2005; Lazarus, 2007).
Hypothyroidism is uncommon in the general population, with a
prevalence of 4–8.5% (Surks et al, 1990, 2004). Reliable data on
hypothyroidism prevalence in cancer patients are not available;
however, some preliminary data suggest a slightly higher
frequency in some tumour types such as melanoma and breast
cancer (Ellerhorst et al, 2003; Jiskra et al, 2004; Shah et al, 2006).
In general, hypothyroidism is particularly common in older age
groups and women (Laurberg et al, 2005). However, in our study,
the median patient age was 61 years (range 42–77) and
male:female ratio was 3:1, indicating that these patient
characteristics do not contribute substantially to the observed
incidence in our patients. Similar patient characteristics were also
found in the study by Rini et al (2007).
On the basis of initial study protocol, we started hormone
replacement therapy in patients with persistent TSH (410mIUl
 1
on day 1 of two consecutive cycles) showing typical symptoms of
hypothyroidism; symptoms resolved in the majority of cases but
not all. The clinical presentation of patients with hypothyroidism
is highly variable and non-specific, and side effects of sunitinib
can be very similar to symptoms of hypothyroidism, certainly
in patients with advanced cancer. Therefore, we cannot be sure
whether fatigue in sunitinib-treated patients can be exclusively
explained by primary hypothyroidism. The hypothesis of Garfield
et al (2007) that hypothyroidism may be associated with improved
outcome in certain types of cancer warrants further investigation,
but hormone replacement therapy should not be withheld if
clinically indicated (Garfield et al, 2007).
Patients with preexisting thyroid function abnormalities may
require higher doses of hormone replacement therapy to maintain
an euthyroid state while treated with sunitinib. In our centre, TSH
levels increased in three patients with a history of well-controlled
hypothyroidism before sunitinib treatment, and adjustment of
hormone replacement therapy was necessary. These patients were
excluded from the prospective evaluation, however, a similar
finding was reported by Rini et al (2007). More recently, De Groot
et al (2006) reported the case of a GIST patient who was treated
simultaneously with sunitinib and L-thyroxine following
previous thyroidectomy and
131I-ablation due to follicular thyroid
carcinoma (de Groot et al, 2006). The patient developed overt
hypothyroidism while receiving sunitinib, and L-thyroxine doses
were increased.
The most common cause of hypothyroidism in the general
population is chronic autoimmune (Hashimoto’s) thyroiditis,
resulting in antibody-mediated destruction of the thyroid tissue
(Laurberg et al, 2005). More than 90% of such patients have
elevated serum TPO or Tg antibodies. Desai et al (2006) reported
TPOAb in 2 out of 42 patients, for whom values were normal
(Desai et al, 2006). Rini et al (2007) measured TgAb (13 abnormal
values of 44 available from 66 enrolled patients) and found no
correlation between the presence of antibodies and either
incidence or severity of other TFT abnormalities (Rini et al,
2007). Accordingly, in our patients, anti-TPO or anti-Tg antibodies
were elevated only in a minority of those with elevated TSH.
Similarly, in the study of Mannavola et al, TPOAb remained
negative during all cycles in all patients who had normal TFTs at
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underlying autoimmune process for developing hypothyroidism in
sunitinib-treated patients.
Mild thyrotoxicosis may, however, precede hypothyroidism
in some but not all patients. Desai et al (2006) identified one
or more TSH concentrations o0.5mIUl
 1, thus indicating
the development of subclinical hyperthyroidism before hypo-
thyroidism (Desai et al, 2006). In our prospective study, we
identified four such cases, suggesting that drug-induced thyroiditis
causing leakage of thyroid hormone into the circulation can
potentially be an underlying mechanism for sunitinib-induced
hypothyroidism.
During sunitinib therapy, most of our patients underwent
repeated CT scan with intravenous iodinated contrast, every 6–8
weeks. Iodine-containing contrast media can transiently elevate
serum TSH, but not free T3 and T4 (Gartner and Weissel, 2004).
Although the effect of repeated exposure to iodine on TSH is
difficult to estimate in our patients, it should be noted that its level
increased already soon after starting sunitinib administration in
our RCC cohort.
Seriously ill patients often show abnormal TFTs not necessarily
associated with thyroid dysfunction, the so-called ‘non-thyroidal
illness (NTI)’ or ‘low T3 syndrome’ (Demers, 2004). Therefore,
peripheral thyroid hormone levels should be interpreted with
caution in these patients. Serum TSH concentrations remain
within reference limits for most NTI patients, although
occasionally a mild transient TSH decrease can be observed at
the beginning of NTI, followed by a rebound to mildly elevated
values during recovery. Thus, NTI cannot be excluded as a
confounding factor in some patients and may result in a slight
overestimation of the percentage of patients developing slight
biochemical TFT abnormalities. In the two other groups defined as
‘(sub)clinical hypo-/hyperthyroidism requiring treatment’, thyroid
abnormalities had to be persistent and/or associated with clinical
symptoms, which is not compatible with NTI.
Primary hypothyroidism is not a common complication of
therapeutic drugs. Among the drugs known to affect thyroid
function are lithium, thioamides, amiodarone and cytokines, such
as interferon and interleukin-2. However, the mechanisms are not
well understood and may also differ from that of sunitinib-induced
hypothyroidism. In our population, most patients with metastatic
RCC had received cytokine therapy before starting sunitinib.
We cannot exclude that this may have influenced the course
of hypothyroidism. It may also explain the difference in thyroid
dysfunction between the RCC (33%) and the GIST (12%)
groups, as the latter did not have to receive cytokine therapy
before sunitinib, and imatinib is not known to induce thyroid
dysfunction.
According to our study, there is no clear association between the
daily dose of sunitinib and developing thyroid dysfunction. Thus,
in contrast to the patient group with normal thyroid function
during treatment, patients developing hypothyroidism underwent,
for the most part, one or two dose reductions for grades III–IV
haematological and non-haematological toxicities, suggesting that
hypothyroidism in these patients reflects a particular susceptibility
to sunitinib rather than dose dependency.
The molecular mechanisms of sunitinib-induced hypothyroidism
are currently unknown. Autoimmune-mediated hypothyroidism
could not be demonstrated as an aetiological factor in this
study, which is in accordance with the results of other groups.
Sunitinib may have a direct effect on the thyroid, for example,
through the inhibition of VEGFR and/or PDGFR. More recent
studies in a mouse model have shown that VEGFR inhibition can
induce capillary regression in various organs, including thyroid.
Moreover, the vasculature of the thyroid had the greatest
regression of all organs (Baffert et al, 2006; Kamba et al, 2006).
Remarkably, in this animal model, thyroid capillaries regenerated
in the absence of VEGFR inhibition. Such a response may explain
the rhythmic pattern of TSH seen in patients treated with the 4/2
schedule. It is interesting that in the studies of Baffert et al (2006)
and Kamba et al (2006), TSH also increased in mice treated with
VEGF inhibition. Sunitinib may also inhibit TPO activity leading to
reduced synthesis of the thyroid hormones, as suggested by
in vitro studies (Wong et al, 2007). Indirectly, sunitinib may affect
the thyroid by interfering with the metabolism of T4/T3 hormones,
or with thyroid hormone action at the pituitary level. In patients
Measure TSH and T4 before starting sunitinib 
Measure TSH on days 1 and 28 in the first 4 cycles of sunitinib treatment 
Measure TSH on day 28 of every 3 cycles  
If TSH>ULN but <10 mIU l–1, suggesting 
high probability of thyroid dysfunction, 
continue to measure TSH on days 1 and  28
of subsequent cycles
If TSH>ULN on day 28 of 3-monthly 
screening, suggesting thyroid dysfunction, 
restart to measure TSH on days 1 and 28 
of each cycle 
Continue to measure TSH after sunitinib 
retrieval: partial recovery of thyroid function 
possible
If thyroid dysfunction, treat appropriately. Be aware that patients 
under hormone replacement therapy may require higher doses of 
hormone replacement therapy to maintain a normal TSH
TSH normal in the first 4 cycles 
If TSH>ULN on day 1 and/or day 28 
If TSH>10 mIU l–1 on day 1  
+ normal T4 but with symptoms of 
hypothyroidism 
or + low T4 
start hormone replacement therapy aiming 
at normalisation of TSH  
Figure 2 Proposed algorithm to diagnose and treat thyroid dysfunction during sunitinib treatment.
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dysfunction seems not to be a frequent side effect (Tamaskar et al,
2008; Wolter et al, manuscript in preparation).
To address the clinical management of thyroid dysfunction in
patients treated with sunitinib, we suggest an algorithm for TFT
monitoring and intervention (Figure 2). In our study, patients who
developed (sub)clinical hypothyroidism requiring treatment
(n¼16) showed TSH elevation early, within median 4 weeks,
following sunitinib initiation. By contrast, some previously
published studies concluded that thyroid dysfunction can occur
later during sunitinib treatment (Table 3). However, these studies
are mainly retrospective, and consistent TSH measurements on
both days 1 and 28 of sunitinib cycles are lacking, which most
probably account for this discrepancy (Desai et al, 2006; Martorella
et al, 2006). Our observations that TFT abnormalities occur rather
early after sunitinib initiation are, however, in better agreement
with the prospective study by Mannavola et al (2007) on 24 GIST
patients, where TSH measurements were performed on both days 1
and 28 and hypothyroidism developed at median of 3 cycles
(range: 1–6). Moreover, we did not observe any patient with
normal TFT during the first cycles of sunitinib who developed
clinical hypothyroidism later in the course of treatment.
In summary, we recommend that all patients treated with
sunitinib have TFTs performed on days 1 and 28 of the first four
cycles (Figure 2). By applying this intensive initial screening, we
consider that we can detect patients at risk of developing sunitinib-
induced thyroid dysfunction early following drug initiation.
Moreover, on the basis of our study, monitoring of patients with
no TFT abnormalities within the four first cycles can be
subsequently performed more rarely, every three cycles, unless
clinically indicated. In these cases, measurements are best
recommended on day 28 rather than on day 1 of a cycle, as the
likelihood to detect TFT abnormalities in highest at this point.
Furthermore, we suggest starting hormone replacement therapy in
patients with persistent TSH 410mIUml
 1 and either low T4 or
normal T4 but with typical symptoms of hypothyroidism. As TSH
level declines and could be normalised by the end of the 2-week
rest period of a sunitinib cycle, decisions to start hormone
replacement should be based on TSH levels on day 1 of a new
sunitinib cycle rather than on day 28 of a current cycle, to avoid
overtreatment. We have encountered such a situation initially in
our practise of treating sunitinib-induced thyroid dysfunction.
Although during our study we initiated hormone replacement after
TSH 410mIUl
 1 on day 1 of two consecutive cycles, we
concluded for our algorithm that it is more prudent to start the
therapy already after one cycle rather than waiting for an
additional cycle. Although an elevated TSH at day 28 of a cycle
may be associated with transient, reversible thyroid dysfunction,
an elevated TSH at day 1 of a cycle, may already indicate a more
pronounced damage to the thyroid, supporting our suggestion for
treatment initiation at this point. Patients with preexisting thyroid
function abnormalities may require higher doses of TSH to
maintain an euthyroid state while treated with sunitinib. Although
our data in measuring TSH after suninitib retrieval is limited, we
also recommend continuing measuring TSH in such cases, as
partial recovery of the thyroid function may occur.
This observation is also supported by the study of Mannavola
et al (2007).
In conclusion, it is important that clinicians consider the
potential side effect of sunitinib on thyroid function. Sunitinib-
induced hypothyroidism is easily manageable with hormone
replacement therapy, and should not withhold the use of sunitinib
when indicated for cancer treatment. Hormone replacement is
necessary to reduce symptoms of hypothyroidism, such as fatigue,
but also to avoid the potentially life-threatening complications of
severe hypothyroidism, such as myxoedema coma.
We admit that our recommendations for thyroid management in
patients under sunitinib may need further validation in a
prospective randomized trial. We believe, however, that our data
so far support the proposed algorithm, and will help clinicians in
their daily practise until more validated guidelines become
available.
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